Table 1 Characterization of study participants
Study participants, n | 19 |
 Subgroup Vibrosphere | 12 |
 Subgroup Galileo | 7 |
Age, years | 54 (52/59) |
Gender, male/female | 11/7 (57.9%/42.1%) |
BMI (kg/m2) | 28 (24/31) |
Diagnosis | |
 ARDS | 9 (47.4%) |
 Trauma | 2 (10.5%) |
 CNS | 8 (42.1%) |
Days between ICU admission and intervention | 15 (8/18) |
Illness severity at ICU admission | |
 SOFA score | 10 (9/13) |
 SAPS-II | 53 (35/78) |
Illness severity at intervention day | |
 SOFA score | 9 (6/10) |
 SAPS-II | 48 (38/52) |
GCS at intervention day | 5 (3/11) |
Sedation, RASS at intervention day | –4 (–4/0) |
Selective medication during intervention, number of patients received and rate in those | |
 Norepinephrine, 12 of 19 patients (rate μg/kg/min) | 0.100 (0.048/0.140) |
 Propofol, 3 of 19 patients (rate mg/kg/min) | 0.033 (0.031/0.033) |
 Midazoloam, 3 of 19 patients (rate mg/kg/min) | 0.002 (0.001/0.003) |
 Sufentanil, 10 of 19 patients (rate μg/kg/min) | 0.011 (0.003/0.020) |
 Clonidin, 6 of 19 patients (rate μg/kg/min) | 0.013 (0.007/0.014) |